Oak Associates’s Quest Diagnostics DGX Stock Holding History

Oak Associates’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.25M	Sell	16,592 -850	-5%	-$165K	0.22%	63
2025 Q4	$3.03M	Hold	17,442	–	–	0.18%	62
2025 Q3	$3.32M	Hold	17,442	–	–	0.2%	60
2025 Q2	$3.13M	Hold	17,442	–	–	0.2%	61
2025 Q1	$2.95M	Hold	17,442	–	–	0.22%	56
2024 Q4	$2.63M	Sell	17,442 -583	-3%	-$90.7K	0.18%	62
2024 Q3	$2.8M	Hold	18,025	–	–	0.19%	59
2024 Q2	$2.47M	Hold	18,025	–	–	0.16%	66
2024 Q1	$2.4M	Sell	18,025 -4,453	-20%	-$578K	0.17%	69
2023 Q4	$3.1M	Hold	22,478	–	–	0.23%	56
2023 Q3	$2.74M	Hold	22,478	–	–	0.23%	60
2023 Q2	$3.16M	Sell	22,478 -5,110	-19%	-$704K	0.25%	56
2023 Q1	$3.9M	Sell	27,588 -6,311	-19%	-$903K	0.32%	54
2022 Q4	$5.3M	Hold	33,899	–	–	0.44%	51
2022 Q3	$4.16M	Buy	33,899 +2,419	+8%	+$319K	0.35%	50
2022 Q2	$4.19M	Hold	31,480	–	–	0.33%	50
2022 Q1	$4.31M	Hold	31,480	–	–	0.26%	54
2021 Q4	$5.45M	Hold	31,480	–	–	0.29%	54
2021 Q3	$4.57M	Hold	31,480	–	–	0.26%	55
2021 Q2	$4.15M	Buy	31,480 +770	+3%	+$101K	0.24%	58
2021 Q1	$3.94M	Buy	30,710 +10	+0%	+$1.23K	0.23%	55
2020 Q4	$3.66M	Hold	30,700	–	–	0.22%	56
2020 Q3	$3.52M	Sell	30,700 -10,000	-25%	-$1.18M	0.23%	59
2020 Q2	$4.64M	Hold	40,700	–	–	0.31%	58
2020 Q1	$3.27M	Hold	40,700	–	–	0.27%	58
2019 Q4	$4.35M	Buy	40,700 +2,245	+6%	+$234K	0.26%	67
2019 Q3	$4.12M	Buy	38,455 +25,000	+186%	+$2.57M	0.25%	68
2019 Q2	$1.37M	Sell	13,455 -11,245	-46%	-$1.08M	0.09%	93
2019 Q1	$2.22M	Hold	24,700	–	–	0.14%	78
2018 Q4	$2.06M	Hold	24,700	–	–	0.15%	82
2018 Q3	$2.67M	Hold	24,700	–	–	0.16%	85
2018 Q2	$2.72M	Sell	24,700 -700	-3%	-$72.9K	0.18%	80
2018 Q1	$2.55M	Sell	25,400 -500	-2%	-$51.2K	0.18%	80
2017 Q4	$2.55M	Sell	25,900 -900	-3%	-$85.3K	0.18%	79
2017 Q3	$2.51M	Sell	26,800 -4,300	-14%	-$456K	0.18%	87
2017 Q2	$3.46M	Hold	31,100	–	–	0.26%	81
2017 Q1	$3.05M	Sell	31,100 -600	-2%	-$57.2K	0.24%	85
2016 Q4	$2.91M	Sell	31,700 -300	-0.9%	-$25.9K	0.29%	78
2016 Q3	$2.61M	Buy	32,000 +6,600	+26%	+$554K	0.27%	81
2016 Q2	$2.07M	Buy	25,400 +4,100	+19%	+$312K	0.25%	93
2016 Q1	$1.52M	Hold	21,300	–	–	0.19%	97
2015 Q4	$1.51M	Hold	21,300	–	–	0.18%	96
2015 Q3	$1.31M	Hold	21,300	–	–	0.17%	96
2015 Q2	$1.54M	Hold	21,300	–	–	0.19%	99
2015 Q1	$1.64M	Hold	21,300	–	–	0.2%	97
2014 Q4	$1.43M	Sell	21,300 -400	-2%	-$25.2K	0.17%	102
2014 Q3	$1.32M	Buy	21,700 +18,150	+511%	+$1.12M	0.16%	105
2014 Q2	$208K	Hold	3,550	–	–	0.03%	171
2014 Q1	$206K	Buy	+3,550	New	+$190K	0.03%	175

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Oak Associates's DGX Position: Q1 2026 in Review

Oak Associates reduced its Quest Diagnostics (DGX) stake by 4.9% in Q1 2026, selling an estimated $165K and leaving 16,592 shares worth $3.25M. The position accounts for 0.22% of the portfolio, ranked #63.

Oak Associates first reported a position in DGX in Q1 2014 and has held it in 49 quarters since. The position peaked at $5.45M in Q4 2021. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Oak Associates held 16,592 shares of Quest Diagnostics worth $3.25M as of Q1 2026.
Oak Associates sold 850 Quest Diagnostics shares in Q1 2026, an estimated $165K.
Quest Diagnostics made up 0.22% of Oak Associates's portfolio in Q1 2026, its #63 holding.
Oak Associates first reported a position in Quest Diagnostics in Q1 2014 and has held it in 49 quarters since.
Oak Associates's Quest Diagnostics position peaked at $5.45M in Q4 2021.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Oak Associates's 13F filing for Q1 2026, filed 14 May 2026.